dt-216
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 11, 2022 (NCT05285540)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Endoplasmic reticulum metallopeptidase 1ANTAGONIST
ERMP1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06874010 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2025 | Design Therapeutics |
| NCT06772870 | Phase 1 | Feb 28, 2025 | Design Therapeutics, Nucleus Network Ltd |
| NCT05573698 | Phase 1 | Sep 27, 2022 | Design Therapeutics |
| NCT05285540 | Phase 1 | Mar 11, 2022 | Design Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Design Therapeutics | For profit | 4 | 4 | 2 | 2022 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1